MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding MiNK Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 23 | 27 | +4 |
| Shares | 126.8K | 204.4K | +77.6K (+61.2%) |
| Value | $1.34M | $2.39M | +$1.05M (+78.9%) |
New holders (7)
Institutions that held MiNK Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| DnB Asset Management AS | 55,142 | $644.6K | 0.00% |
| Citadel Advisors LLC | 15,440 | $180.5K | 0.00% |
| US Bancorp | 1,995 | $23.3K | 0.00% |
| Federation des caisses Desjardins du Quebec | 500 | $5.84K | 0.00% |
| Barclays PLC | 24 | $281 | 0.00% |
| Wells Fargo & Company | 2 | $23 | 0.00% |
| LifeSteps Financial, Inc. | 2 | $23 | 0.00% |
Sold out (3)
Institutions that held MiNK Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Annis Gardner Whiting Capital Advisors, LLC | 200 | $2.11K |
| Citigroup Inc | 91 | $958 |
| Pinnacle Wealth Planning Services, Inc. | 5 | $53 |